These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Prediction of the binding free energies of new TIBO-like HIV-1 reverse transcriptase inhibitors using a combination of PROFEC, PB/SA, CMC/MD, and free energy calculations. Eriksson MA, Pitera J, Kollman PA. J Med Chem; 1999 Mar 11; 42(5):868-81. PubMed ID: 10072684 [Abstract] [Full Text] [Related]
6. Analyses of activity for factor Xa inhibitors based on Monte Carlo simulations. Ostrovsky D, Udier-Blagović M, Jorgensen WL. J Med Chem; 2003 Dec 18; 46(26):5691-9. PubMed ID: 14667222 [Abstract] [Full Text] [Related]
7. Docking of non-nucleoside inhibitors: neotripterifordin and its derivatives to HIV-1 reverse transcriptase. Zhou Z, Madrid M, Madura JD. Proteins; 2002 Dec 01; 49(4):529-42. PubMed ID: 12402361 [Abstract] [Full Text] [Related]
9. CoMFA 3D-QSAR analysis of HIV-1 RT nonnucleoside inhibitors, TIBO derivatives based on docking conformation and alignment. Zhou Z, Madura JD. J Chem Inf Comput Sci; 2004 Dec 01; 44(6):2167-78. PubMed ID: 15554687 [Abstract] [Full Text] [Related]
10. Monte Carlo calculations on HIV-1 reverse transcriptase complexed with the non-nucleoside inhibitor 8-Cl TIBO: contribution of the L100I and Y181C variants to protein stability and biological activity. Smith MB, Lamb ML, Tirado-Rives J, Jorgensen WL, Michejda CJ, Ruby SK, Smith RH. Protein Eng; 2000 Jun 01; 13(6):413-21. PubMed ID: 10877852 [Abstract] [Full Text] [Related]
12. Bridge water mediates nevirapine binding to wild type and Y181C HIV-1 reverse transcriptase--evidence from molecular dynamics simulations and MM-PBSA calculations. Treesuwan W, Hannongbua S. J Mol Graph Model; 2009 Jun 01; 27(8):921-9. PubMed ID: 19414275 [Abstract] [Full Text] [Related]
13. Understanding the basis of resistance in the irksome Lys103Asn HIV-1 reverse transcriptase mutant through targeted molecular dynamics simulations. Rodríguez-Barrios F, Gago F. J Am Chem Soc; 2004 Dec 01; 126(47):15386-7. PubMed ID: 15563158 [Abstract] [Full Text] [Related]
14. Effect of a bound non-nucleoside RT inhibitor on the dynamics of wild-type and mutant HIV-1 reverse transcriptase. Zhou Z, Madrid M, Evanseck JD, Madura JD. J Am Chem Soc; 2005 Dec 14; 127(49):17253-60. PubMed ID: 16332074 [Abstract] [Full Text] [Related]
16. A group center overlap based approach for "3D QSAR" studies on TIBO derivatives. Sapre NS, Gupta S, Pancholi N, Sapre N. J Comput Chem; 2009 Apr 30; 30(6):922-33. PubMed ID: 18785154 [Abstract] [Full Text] [Related]
17. Predicting binding modes from free energy calculations. Nervall M, Hanspers P, Carlsson J, Boukharta L, Aqvist J. J Med Chem; 2008 May 08; 51(9):2657-67. PubMed ID: 18410080 [Abstract] [Full Text] [Related]
18. Combining docking, molecular dynamics and the linear interaction energy method to predict binding modes and affinities for non-nucleoside inhibitors to HIV-1 reverse transcriptase. Carlsson J, Boukharta L, Aqvist J. J Med Chem; 2008 May 08; 51(9):2648-56. PubMed ID: 18410085 [Abstract] [Full Text] [Related]
19. Estimation of binding affinities for HEPT and nevirapine analogues with HIV-1 reverse transcriptase via Monte Carlo simulations. Rizzo RC, Tirado-Rives J, Jorgensen WL. J Med Chem; 2001 Jan 18; 44(2):145-54. PubMed ID: 11170624 [Abstract] [Full Text] [Related]
20. Revealing interaction mode between HIV-1 reverse transcriptase and diaryltriazine analog inhibitor. Li Z, Han J, Chen HF. Chem Biol Drug Des; 2008 Nov 18; 72(5):350-9. PubMed ID: 19012571 [Abstract] [Full Text] [Related] Page: [Next] [New Search]